Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential? (NASDAQ:TECH)

Institutional investors love wide-moat businesses that can reliably generate exceptional margins and cash flows with relatively little competitive risk. They also love companies that can reliably generate above-average growth, and when you combine the two, the valuation multiples can really jump. Such has historicallyAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote t ...